Results 221 to 230 of about 48,471 (314)

B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab‐Mediated B Cell Depletion in Rheumatic Diseases

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Rituximab (RTX), an anti‐CD20 monoclonal antibody, has been used to treat autoimmune diseases such as rheumatoid arthritis (RA). However, variability in therapeutic response to RTX remains a challenge. Here, a systems model is developed to mimic B cell differentiation leading to antibody‐secreting cells (ASCs), including plasmablasts (PBs) and
Tomohisa Nakada, Donald E. Mager
wiley   +1 more source

IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies

open access: green
Mounish Nuthalapati   +5 more
openalex   +2 more sources

Pharmacokinetics of Odronextamab, A Bispecific T‐Cell‐Engaging Antibody, in Adult Patients With Relapsed or Refractory B‐Cell Non‐Hodgkin Lymphoma

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Non‐Hodgkin lymphoma (NHL) is the fifth most common malignancy and accounts for 5% of all cancers in the US, with the largest proportion being B‐cell CD20 positive NHL. Odronextamab is a CD20xCD3 IgG4 bispecific T‐cell‐engaging monoclonal antibody under development for the treatment of relapsed or refractory (R/R) B‐NHL. The objectives of this
Marçal Bravo Padros   +5 more
wiley   +1 more source

New cardiac manifestation of IgG4-related disease: a case report

open access: green, 2020
Marina Pourafkari   +5 more
openalex   +2 more sources

An Overlapping Case of Lupus Nephritis and IgG4-Related Kidney Disease

open access: diamond, 2015
Mazen Zaarour   +4 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy